Efficacy of Topical Cyclosporine 0.05% in the Prevention of Ocular Surface Inflammation Secondary to Pterygia

Innovative Medical

Status and phase: Completed; Phase 4

Conditions: Pterygia

Treatments: Drug: Topical Cyclosporine

Study type: Interventional

Funder types: Industry

Identifiers

NCT00383396

1963

Details and patient eligibility

About

To Determine if topical cyclosporine 0.05% BID prevents recurrent inflammation and improves comfort in eyes with pterygia.

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• pts with symptomatic pterygia unresponsive to palliative treatment.